Hemcheck has received a first follow-up order from its Irish distributor, Cruinn Diagnostics (“Cruinn”). The order regarding bgs-Test, is of lower economic value, but is linked to a university hospital that has a clear interest in evaluating and in the next stage possibly implementing the solution in its daily operations.
– It is very good that we have received this follow-up order as it shows that Cruinn is active and that there is a clear interest from the market. Recently, after the pandemic restrictions have been lifted, we have in general noticed higher activity among our distributors. It is also positive that it is the bgs-Test that is in demand and the opportunity to go to the next stage with the hospital as the end customer is something we of course hope for, says Joen Averstad, CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel: +46 76 108 8191
Read more at https://www.cruinndiagnostics.ie/
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.